DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know

DaVita HealthCare (DVA) ended the recent trading session at $139.43, demonstrating a -1.23% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.38%. Prior to today's trading, shares of the kidney dialysis provider had gained 3.08% outpaced the Medical sector's loss of 1.94% and lagged the S&P 500's gain of 5.35%.The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is slated to reveal its earnings on August 5, 2025. The company's earnings per share (EPS) are projected to be $2.7, reflecting a 4.25% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.3 billion, up 3.5% from the year-ago period. For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.76 per share and a revenue of $13.48 billion, signifying shifts of +11.16% and +5.15%, respectively, from the last year. Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold). Looking at its valuation, DaVita HealthCare is holding a Forward P/E ratio of 13.13. This denotes a discount relative to the industry average Forward P/E of 17.82. One should further note that DVA currently holds a PEG ratio of 0.97. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.63 as trading concluded yesterday. The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 55, positioning it in the top 23% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks